A Study of Suvorexant in Patients With Multiple Sclerosis Fatigue and Insomnia

Summary

This study assesses the safety, tolerability, and efficacy of suvorexant in multiple sclerosis patients. Enrolled subjects will receive 2 weeks of treatment during treatment period 1 with either suvorexant or matching placebo (1:1). After treatment period 1, subjects will undergo a washout period of 1 week then 2 weeks of the alternate treatment (either suvorexant or placebo). The primary hypothesis is that suvorexant will provide greater improvement in sleep, as measured by symptom rating scales, compared to placebo.

Timeline

Start

2017-03-28

Primary completion

2022-03-21

Completion

2022-03-21

Drugs

Indications